CEO Insights India

As the industry continues to evolve through technological advancements, global expansion, stringent compliance require -ments, and increasing patient expec -tations, effective leadership has become more important than ever. Strong leaders are responsible for driving operational excellence, fostering innovation, managing complex supply chains, ensuring regulatory compliance, and building resilient organizations capable of sustaining long-term growth.

Their ability to navigate challenges while aligning people, processes, and strategy is often the defining factor behind an organization’s success. One such accomplished leader is Chetan Shah, Chief Operating Officer and Director at Senores Pharmaceuticals, whose extensive career reflects a deep commitment to operational excellence and organizational growth.

Chetan Shah began his professional journey with GMM Pfaudler and subsequently worked with Cadmach and Ingersoll Rand, gaining valuable industrial experience during his initial years. He then joined Cadila Pharmaceuticals during a transformative phase following the company’s split and spent over a decade contributing across multiple functions, including production coordi- nation, HR management, projects, cost-reduction initiatives, cross-functional team leadership, and end-to-end supply chain management for both domestic and international markets.

Seeking broader business exposure, Chetan Shah joined Reliance Retail at a time when organized retail was emerging in India, where he gained unique insights into large-scale national supply chain operations. He later served as Global Supply Chain Head at Torrent Pharma-ceuticals, contributing to the company’s growth and integration initiatives.

Today, at Senores Pharmaceuticals, he oversees Strategic operations – manufacturing, supplychain for domestic/International markets, Projects, technology upgradation and capacity expansion, risk management, IT, management information systems, and Organization behavioral aspects.

Throughout his career, Chetan Shah has played a pivotal role in helping organizations prepare for the next phase of growth. His ability to manage complex challenges, optimize resources, and build high-performing teams has consistently delivered results. Driven by a strong sense of achievement he remains passionate about mentoring professionals, leading large teams, and creating sustainable value for organizations. Let’s read on.

How is the adoption of advanced technologies re- shaping pharmaceutical research and development, and what key benefits are these innovations delivering in terms of speed, accuracy, and patient outcomes?

Advanced technologies are transforming pharmaceutical research and development by making processes faster, more accurate, and patient-centric. With the integration of AI, machine learning, deep learning, and robotics I see tremendous oppor -tunities to accelerate drug discovery and development.

These technologies enable the rapid analysis of vast biological and chemical datasets, helping predict drug efficacy, toxicity, and potential side effects with greater precision. AI also optimizes clinical trial processes, reducing development timelines and costs while supporting the creation of personalized therapies.

Robotics further enhances manufacturing efficiency by improving accuracy, consistency, and productivity with minimal human intervention, ultimately leading to better patient outcomes.

What key trends are defining the global generic pharmaceutical market today, and how are companies adapting to changing regulations, pricing pre- ssures, and growing competition while main- taining innovation and quality standards?

The global generic pharmaceutical market is increasingly shifting from traditional, low-margin products toward complex generics, biosimilars, and oncology therapies. Rising healthcare costs and resource expenses are driving this transition.

I believe growth is now being fueled by innovative formulations such as inhalers, sustained release products and biosimilars. Companies are strengthening local manufacturing of APIs and raw materials to address geopolitical uncertainties and supplychain risks.

Strategic mergers and acquisitions are helping organizations enhance scale, regulatory capabilities, and R&D strength. Additionally, many manufacturers are focusing on branded generics and incremental product innovations that improve drug delivery, minimize side effects, and enhance patient compliance.

Tell us about your leadership approach. What are the guidelines or methodologies you follow as a leader?

My leadership philosophy is simple: lead from the front and set an example. I focus on building strong systems, solving problems quickly, and making timely decisions that balance quality, cost, and speed. I maintain close engagement with

team leaders, understand their challenges, and support them in execution.

I believe in selecting the right talent, empowering people with authority and accountability, and continuously developing future leaders through training and mentoring.

Creating high-performing teams, encour -aging ownership, ensuring fair performance evaluation, and driving technology upgrades and project execution are key elements of my leadership approach.

How do you keep yourself up-to-date with ongoing industry trends to steer your organization towards the future?

I stay informed through a combination of industry magazines, business journals, global news sources, and professional networks. Regular interactions with colleagues and industry peers provide valuable insights into emerging trends and best practices.

I also closely follow developments in pharmaceutical innovation, technology, and regulatory changes through various platforms. Participation in mergers, acquisitions, collaborations, and strategic business initiatives further broadens my perspective and helps me understand evolving market dynamics.

Continuous learning and staying connected with industry developments enable me to make informed decisions and guide the organization toward sustainable growth and future opportunities.

What is the future destination you are heading towards?

I am always motivated by opportunities that bring greater responsibility and complexity. My goal is to continue learning, achieving new milestones, and contributing to organizational growth through effective leadership and strategic execution.

I believe that taking on challenging roles not only enhances personal and professional development but also creates greater value for the organization and the industry.

Ultimately, I want to contribute meaning -fully to the healthcare sector by supporting innovation improving operational excellence, and helping deliver better healthcare solutions that positively impact patients and society.

Chetan Shah, Chief Operating Officer & Director, Senores Pharmaceuticals

Chetan Shah is the Chief Operating Officer and Director at Senores Pharmaceuticals, with over three decades of experience across pharmaceuticals, manufacturing, retail, and supply chain management.

He has held leadership roles at Cadila Pharma- ceuticals, Reliance Retail, and Torrent Pharmaceuticals, driving opera-tional excellence business transformation, strategic growth, and organizational development.